---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045338"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:40:37.550311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abeona Q3 net loss $30.3M; FDA sets pz-cel PDUFA Apr 29, 2025

## Summary
- Net loss Q3 2024: $30.3M vs $11.8M YoY; includes $15.2M warrant revaluation loss.
- Cash, equivalents and investments $110.0M; down $13M from Q2; cash runway into 2026.
- FDA accepted pz-cel BLA resubmission; PDUFA target action date April 29, 2025.
- CMS granted pz-cel product-specific code and Pre-MDC MS-DRG 018 reimbursement.
- New U.S. patent issued for pz-cel (exp. 2037); lease for added manufacturing capacity.

## SEC filing metadata
- accession: 0001493152-24-045338
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/0001493152-24-045338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045338
- JSON: https://secwatch.observer/filing/0001493152-24-045338.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.